The stock of InflaRx N.V. (NASDAQ:IFRX) is a huge mover today! The stock increased 7.79% or $3.03 during the last trading session, reaching $41.91. About 310,856 shares traded or 128.81% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since April 7, 2018 and is uptrending. It has outperformed by 35.02% the S&P500.
The move comes after 8 months positive chart setup for the $1.09 billion company. It was reported on Apr, 7 by Barchart.com. We have $44.42 PT which if reached, will make NASDAQ:IFRX worth $65.28 million more.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” on November 08, 2018, also Globenewswire.com with their article: “InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum – GlobeNewswire” published on February 27, 2019, Globenewswire.com published: “InflaRx N.V. To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclonal Antibody IFX-1 – GlobeNewswire” on August 28, 2018. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors – GlobeNewswire” published on September 21, 2018 as well as Seekingalpha.com‘s news article titled: “InflaRx down 14% – Seeking Alpha” with publication date: November 19, 2018.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $1.09 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.